Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (7): 698-703.doi: 10.19982/j.issn.1000-6621.20220017
• Original Articles • Previous Articles Next Articles
GAO Li, PANG Xue-wen, ZHANG Guo-qin, LI Jing-xin, ZHANG Fan()
Received:
2022-01-28
Online:
2022-07-10
Published:
2022-07-06
Contact:
ZHANG Fan
E-mail:zhangfan66@tj.gov.cn
CLC Number:
GAO Li, PANG Xue-wen, ZHANG Guo-qin, LI Jing-xin, ZHANG Fan. Analysis of risk factors for recurrence within 2 years after successful treatment of newly treated active pulmonary tuberculosis in Tianjin[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 698-703. doi: 10.19982/j.issn.1000-6621.20220017
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20220017
变量 | 复发 | 未复发 | HR(95%CI)值 | P值 | |||||
---|---|---|---|---|---|---|---|---|---|
例数 | 构成比(%) | 例数 | 构成比(%) | ||||||
性别 | |||||||||
女性 | 79 | 3.00 | 2558 | 97.00 | 0.000 | ||||
男性 | 228 | 4.16 | 5250 | 95.84 | 1.398(1.082~1.806) | 0.010 | |||
年龄(岁) | |||||||||
<20 | 12 | 2.26 | 518 | 97.74 | 0.000 | ||||
20~39 | 72 | 2.53 | 2771 | 97.47 | 0.722(0.606~2.058) | 0.722 | |||
40~59 | 114 | 5.07 | 2136 | 94.93 | 2.262(1.248~4.100) | 0.007 | |||
≥60 | 109 | 4.37 | 2383 | 95.63 | 1.948(1.073~3.536) | 0.028 | |||
职业 | |||||||||
学生教师 | 13 | 1.78 | 716 | 98.22 | 0.000 | ||||
工人 | 11 | 3.31 | 321 | 96.69 | 1.875(0.840~4.185) | 0.125 | |||
农民/民工/牧民 | 41 | 4.28 | 916 | 95.72 | 2.429(1.302~4.533) | 0.005 | |||
干部、职员 | 39 | 2.88 | 1313 | 97.12 | 1.625(0.868~3.045) | 0.129 | |||
离退休 | 46 | 3.89 | 1136 | 96.11 | 2.208(1.193~4.086) | 0.012 | |||
家务/待业 | 144 | 4.67 | 2941 | 95.33 | 2.651(1.503~4.677) | 0.001 | |||
医务工作 | 1 | 1.35 | 73 | 98.65 | 0.756(0.099~5.780) | 0.788 | |||
餐饮服务业 | 1 | 3.23 | 30 | 96.77 | 1.811(0.237~13.841) | 0.567 | |||
职业不详 | 11 | 2.95 | 362 | 97.05 | 1.664(0.746~3.715) | 0.214 | |||
患者来源 | |||||||||
转诊追踪 | 68 | 3.93 | 1662 | 96.07 | 0.000 | ||||
因症就诊/推荐 | 238 | 3.77 | 6076 | 96.23 | 0.955(0.790~1.250) | 0.735 | |||
接触者检查/体检 | 1 | 1.41 | 70 | 98.59 | 0.429(0.059~3.093) | 0.401 | |||
病原学结果 | |||||||||
病原学阴性 | 108 | 2.92 | 3585 | 97.08 | 0.000 | ||||
病原学阳性 | 190 | 5.50 | 3267 | 94.50 | 1.904(1.503~2.411) | 0.000 | |||
单纯结核性胸膜炎 | 9 | 0.95 | 934 | 99.05 | 0.340(0.172~0.671) | 0.001 | |||
无病原学结果 | 0 | 0.00 | 22 | 100.00 | 0.000(0.000~2.413E) | 0.931 | |||
变量 | 复发 | 未复发 | HR(95%CI)值 | P值 | |||||
例数 | 构成比(%) | 例数 | 构成比(%) | ||||||
耐药情况 | |||||||||
敏感 | 190 | 5.37 | 3346 | 94.63 | 0.000 | ||||
利福平耐药 | 1 | 1.10 | 90 | 98.90 | 2.556(0.028~1.437) | 0.110 | |||
非利福平耐药 | 38 | 11.62 | 327 | 88.38 | 15.067(1.407~2.824) | 0.000 | |||
未获得耐药信息 | 78 | 1.89 | 4045 | 98.11 | 0.346(0.266~0.450) | 0.000 | |||
总延误时间(d) | |||||||||
<28 | 119 | 3.83 | 2987 | 96.17 | 0.000 | ||||
≥28 | 188 | 3.75 | 4821 | 96.25 | 0.981(0.780~1.234) | 0.870 | |||
合并糖尿病 | |||||||||
否 | 227 | 3.63 | 6019 | 96.37 | 0.000 | ||||
是 | 57 | 6.32 | 845 | 93.68 | 1.766(1.321~2.361) | 0.000 | |||
未知 | 23 | 2.38 | 944 | 97.62 | 0.649(0.423~0.997) | 0.048 | |||
诊疗机构级别 | |||||||||
区级 | 52 | 3.96 | 1260 | 96.04 | 0.000 | ||||
省级 | 255 | 3.75 | 6548 | 96.25 | 0.945(0.701~1.273) | 0.710 | |||
2个月末痰涂片结果 | |||||||||
涂阴 | 257 | 3.63 | 6822 | 96.37 | 0.000 | ||||
涂阳 | 31 | 7.71 | 371 | 92.29 | 2.174(1.498~3.156) | 0.000 | |||
未查痰 | 19 | 3.00 | 615 | 97.00 | 0.823(0.516~1.311) | 0.412 | |||
5个月末痰涂片结果 | |||||||||
涂阴 | 280 | 3.91 | 6887 | 96.09 | 0.000 | ||||
涂阳 | 3 | 6.00 | 47 | 94.00 | 1.544(0.495~4.817) | 0.454 | |||
未查痰 | 24 | 2.67 | 874 | 97.33 | 0.680(0.448~1.032) | 0.070 |
变量 | 赋值 | 变量 | 赋值 | |
---|---|---|---|---|
性别 | 女性=0,男性=1 | 耐药情况 | 敏感=0,利福平耐药=1,非利福平耐药=2,未获得耐药信息=3 | |
年龄 | <20岁=0,20~39岁=1,40~59岁=2,≥60岁=3 | |||
总延误时间 | <28d=0,≥28d=1 | |||
职业 | 儿童、学生、教师=0;工人=1,农民/民工/牧民=2,干部职员=3,离退休=4,家务/待业=5,医务工作=6,餐饮服务业=7,职业不详=8 | |||
是否合并糖尿病 | 否=0,是=1,未知=2 | |||
诊疗单位级别 | 区级=0,省级=1 | |||
患者来源 | 转诊追踪=0,因症就诊/推荐=1,接触者检查/体检=2 | |||
2个月末痰涂片结果 | 涂阴=0,涂阳=1,未查痰=2 | |||
病原学结果 | 病原学阴性=0,病原学阳性=1,单纯结核性胸膜炎=2,无病原学结果=3 | |||
5个月末痰涂片结果 | 涂阴=0,涂阳=1,未查痰=2 |
变量 | β值 | s | Wald χ2值 | aHR(95%CI)值 | P值 |
---|---|---|---|---|---|
男性 | 0.278 | 0.132 | 4.478 | 1.321(1.021~1.710) | 0.034 |
40~59岁 | 0.797 | 0.304 | 6.899 | 2.220(1.224~4.025) | 0.009 |
≥60岁 | 0.66 | 0.304 | 4.711 | 1.935(1.066~3.513) | 0.030 |
工人/民工/牧民 | 0.834 | 0.319 | 6.844 | 2.303(1.233~4.303) | 0.009 |
家务及待业 | 0.85 | 0.291 | 8.519 | 2.340(1.322~4.143) | 0.004 |
病原学阳性 | 0.579 | 0.122 | 22.713 | 1.785(1.407~2.265) | 0.000 |
单纯结核性胸膜炎 | -1.369 | 0.370 | 13.657 | 0.254(0.123~0.526) | 0.000 |
非利福平耐药 | 0.677 | 0.178 | 14.508 | 1.968(1.389~2.789) | 0.000 |
2个月末痰涂片阳性 | 0.417 | 0.196 | 4.522 | 1.517(1.033~2.228) | 0.033 |
合并糖尿病 | 0.323 | 0.151 | 4.599 | 1.382(1.028~1.857) | 0.032 |
[1] | World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021. |
[2] | 段琼红, 陈聪, 张正斌, 等. 武汉市首次复治涂阳肺结核治疗结局及影响因素分析. 中国防痨杂志, 2013, 35(10):788-792. |
[3] |
田攀文, 文富强. 肺结核复发危险因素的研究进展. 中华肺部疾病杂志(电子版), 2013, 6(2):159-161. doi: 10.3877/cma.j.issn.1674-6902.2013.02.015.
doi: 10.3877/cma.j.issn.1674-6902.2013.02.015 |
[4] |
陈松华, 吴蓓蓓, 柳正卫, 等. 浙江省结核病耐药状况分析. 预防医学, 2016, 28(8):757-761,765. doi: 10.19485/j.cnki.issn1007-0931.
doi: 10.19485/j.cnki.issn1007-0931 |
[5] | 林森林, 梅建, 高谦, 等. 结核病复发的流行病学研究进展. 中华流行病学杂志, 2013, 34(4):409-412. |
[6] | 中华人民共和国卫生部. WS 288—2008 肺结核诊断标准. 2008-01-16. |
[7] | 中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 2017-11-09. |
[8] | World Health Organization. Definitions and reporting frame-work for tuberculosis-2013 revision. Geneva: World Health Organization, 2013. |
[9] |
彭红, 虞浩, 姜洁, 等. 江苏省初治结核病复发流行病学特征及影响因素. 江苏预防医学, 2019, 30(4):355-359. doi: 10.13668/j.issn.1006-9070.
doi: 10.13668/j.issn.1006-9070 |
[10] |
邱玉冰, 许琳, 杨蕊, 等. 云南省成功治疗肺结核患者5年复发情况及影响因素研究. 预防医学, 2020, 32(6):559-562. doi: 10.19485/j.cnki.issn2096-5087.
doi: 10.19485/j.cnki.issn2096-5087 |
[11] | 沈鑫. 结核病复发及结核分枝杆菌二线药物耐药性的研究. 上海:复旦大学, 2012. |
[12] |
Shen X, Yang C, Wu J, et al. Recurrent tuberculosis in an urban area in China: Relapse or exogenous reinfection? Tuberculosis (Edinb), 2017, 103:97-104. doi: 10.1016/j.tube.2017.01.007.
doi: 10.1016/j.tube.2017.01.007 |
[13] |
地尔木拉提·吐孙, 麦维兰江·阿不力米提, 刘振江, 等. 2011—2020年新疆喀什地区初治肺结核患者复发影响因素分析. 中国防痨杂志, 2021, 43(11):1176-1182. doi: 10.3969/j.issn.1000-6621.2021.11.013.
doi: 10.3969/j.issn.1000-6621.2021.11.013 |
[14] |
张红伟, 陈曦, 孙闪华, 等. 北京市初治肺结核患者治疗成功后复发情况及危险因素分析. 疾病监测, 2021, 36(8):818-823. doi: 10.3784/jbjc.202106110332.
doi: 10.3784/jbjc.202106110332 |
[15] |
雷蓉蓉, 汪清雅, 张婷. 重庆市肺结核患者复发情况及影响因素分析. 中国热带医学, 2020, 20(11):1092-1095. doi: 10.13604/j.cnki.46-1064/r.
doi: 10.13604/j.cnki.46-1064/r |
[16] |
戴志松, 陈堃, 林淑芳, 等. 福建省成功治疗的肺结核患者10年复发情况及影响因素分析. 疾病监测, 2021, 36(11):1152-1158. doi: 10.3784/jbjc.202106300378.
doi: 10.3784/jbjc.202106300378 |
[17] |
Lee H, Kim J. A study on the relapse rate of tuberculosis and related factors in Korea using nationwide tuberculosis notification data. Osong Public Health Res Perspect, 2014, 5(Suppl):S8-S17. doi: 10.1016/j.phrp.2014.11.001.
doi: 10.1016/j.phrp.2014.11.001 URL |
[18] |
Odone A, Houben RM, White RG, et al. The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets. Lancet Diabetes Endocrinol, 2014, 2(9):754-764. doi: 10.1016/S2213-8587(14)70164-0.
doi: 10.1016/S2213-8587(14)70164-0 URL |
[19] |
Marx FM, Dunbar R, Enarson DA, et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis, 2014, 58(12):1676-1683. doi: 10.1093/cid/ciu186.
doi: 10.1093/cid/ciu186 URL |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||